STAT3-IN-18 inhibits the JAK2-STAT3 signaling pathway in breast cancer (BC) cells, exhibiting antiproliferative activity; induces apoptosis by activating caspase-3 and cleaving poly(ADP-ribose) polymerase (PARP); promotes dendritic cell maturation and antigen presentation; and demonstrates in vivo safety.